March 3 (Reuters) - Nuvation Bio Inc NUVB.N:
NUVATION BIO SECURES UP TO $250 MILLION IN NON-DILUTIVE FINANCINGS FROM SAGARD HEALTHCARE PARTNERS
NUVATION BIO INC: PROCEEDS FROM ROYALTY INTEREST FINANCING EXPECTED TO FULLY FUND U.S. COMMERCIAL LAUNCH OF TALETRECTINIB
Source text: ID:nBw5gXy34a
Further company coverage: NUVB.N
(Reuters.Briefs@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.